Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial

NCT02979548 is registered in ClinicalTrials.gov with Dr Atul Sharma as lead sponsor.

NCT NCT02979548
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02979548 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Evaluate the Anti-emetic Effect of Aprepitant as an add-on Therapy in Children and Adolescents Receiving AML Remission Induction Chemotherapy: An Investigator-initiated, Randomized, Open Label Trial
Lead sponsor
Dr Atul Sharma
Phase
Phase 3
Overall status
Unknown status
Start date
November 30, 2016
Completion date
December 31, 2018
Enrollment
116 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, chemotherapy induced vomiting